These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 22488632)

  • 1. Serum metabolic profiling in inflammatory bowel disease.
    Williams HR; Willsmore JD; Cox IJ; Walker DG; Cobbold JF; Taylor-Robinson SD; Orchard TR
    Dig Dis Sci; 2012 Aug; 57(8):2157-65. PubMed ID: 22488632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum and urine metabolomic fingerprinting in diagnostics of inflammatory bowel diseases.
    Dawiskiba T; Deja S; Mulak A; Ząbek A; Jawień E; Pawełka D; Banasik M; Mastalerz-Migas A; Balcerzak W; Kaliszewski K; Skóra J; Barć P; Korta K; Pormańczuk K; Szyber P; Litarski A; Młynarz P
    World J Gastroenterol; 2014 Jan; 20(1):163-74. PubMed ID: 24415869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of inflammatory bowel disease with urinary metabolic profiling.
    Williams HR; Cox IJ; Walker DG; North BV; Patel VM; Marshall SE; Jewell DP; Ghosh S; Thomas HJ; Teare JP; Jakobovits S; Zeki S; Welsh KI; Taylor-Robinson SD; Orchard TR
    Am J Gastroenterol; 2009 Jun; 104(6):1435-44. PubMed ID: 19491857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative metabolomic profiling of serum, plasma, and urine by (1)H NMR spectroscopy discriminates between patients with inflammatory bowel disease and healthy individuals.
    Schicho R; Shaykhutdinov R; Ngo J; Nazyrova A; Schneider C; Panaccione R; Kaplan GG; Vogel HJ; Storr M
    J Proteome Res; 2012 Jun; 11(6):3344-57. PubMed ID: 22574726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of Exhaled Breath Volatile Organic Compounds in Inflammatory Bowel Disease: A Pilot Study.
    Hicks LC; Huang J; Kumar S; Powles ST; Orchard TR; Hanna GB; Williams HR
    J Crohns Colitis; 2015 Sep; 9(9):731-7. PubMed ID: 26071410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease.
    Bjerrum JT; Steenholdt C; Ainsworth M; Nielsen OH; Reed MA; Atkins K; Günther UL; Hao F; Wang Y
    BMC Med; 2017 Oct; 15(1):184. PubMed ID: 29032767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary NMR metabolomic profiles discriminate inflammatory bowel disease from healthy.
    Stephens NS; Siffledeen J; Su X; Murdoch TB; Fedorak RN; Slupsky CM
    J Crohns Colitis; 2013 Mar; 7(2):e42-8. PubMed ID: 22626506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased Tryptophan Metabolism Is Associated With Activity of Inflammatory Bowel Diseases.
    Nikolaus S; Schulte B; Al-Massad N; Thieme F; Schulte DM; Bethge J; Rehman A; Tran F; Aden K; Häsler R; Moll N; Schütze G; Schwarz MJ; Waetzig GH; Rosenstiel P; Krawczak M; Szymczak S; Schreiber S
    Gastroenterology; 2017 Dec; 153(6):1504-1516.e2. PubMed ID: 28827067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrative Analysis of the Inflammatory Bowel Disease Serum Metabolome Improves Our Understanding of Genetic Etiology and Points to Novel Putative Therapeutic Targets.
    Di'Narzo AF; Houten SM; Kosoy R; Huang R; Vaz FM; Hou R; Wei G; Wang W; Comella PH; Dodatko T; Rogatsky E; Stojmirovic A; Brodmerkel C; Perrigoue J; Hart A; Curran M; Friedman JR; Zhu J; Agrawal M; Cho J; Ungaro R; Dubinsky MC; Sands BE; Suárez-Fariñas M; Schadt EE; Colombel JF; Kasarskis A; Hao K; Argmann C
    Gastroenterology; 2022 Mar; 162(3):828-843.e11. PubMed ID: 34780722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential of metabolic and lipid profiling in inflammatory bowel diseases: A pilot study.
    Tefas C; Ciobanu L; Tanțău M; Moraru C; Socaciu C
    Bosn J Basic Med Sci; 2020 May; 20(2):262-270. PubMed ID: 31368421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ulcerative colitis, Crohn's disease, and irritable bowel syndrome have different profiles of extracellular matrix turnover, which also reflects disease activity in Crohn's disease.
    Mortensen JH; Manon-Jensen T; Jensen MD; Hägglund P; Klinge LG; Kjeldsen J; Krag A; Karsdal MA; Bay-Jensen AC
    PLoS One; 2017; 12(10):e0185855. PubMed ID: 29028807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein profiles of peripheral blood mononuclear cells are useful for differential diagnosis of ulcerative colitis and Crohn's disease.
    Hatsugai M; Kurokawa MS; Kouro T; Nagai K; Arito M; Masuko K; Suematsu N; Okamoto K; Itoh F; Kato T
    J Gastroenterol; 2010 May; 45(5):488-500. PubMed ID: 20049485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating levels of chemerin and adiponectin are higher in ulcerative colitis and chemerin is elevated in Crohn's disease.
    Weigert J; Obermeier F; Neumeier M; Wanninger J; Filarsky M; Bauer S; Aslanidis C; Rogler G; Ott C; Schäffler A; Schölmerich J; Buechler C
    Inflamm Bowel Dis; 2010 Apr; 16(4):630-7. PubMed ID: 19714754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unique Metabolomic and Lipidomic Profile in Serum From Patients With Crohn's Disease and Ulcerative Colitis Compared With Healthy Control Individuals.
    Tews HC; Schmelter F; Kandulski A; Büchler C; Schmid S; Schlosser S; Elger T; Loibl J; Sommersberger S; Fererberger T; Gunawan S; Kunst C; Gülow K; Bettenworth D; Föh B; Maaß C; Solbach P; Günther UL; Derer S; Marquardt JU; Sina C; Müller M
    Inflamm Bowel Dis; 2024 Dec; 30(12):2405-2417. PubMed ID: 38156773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted Analysis of Serum Proteins Encoded at Known Inflammatory Bowel Disease Risk Loci.
    Drobin K; Assadi G; Hong MG; Andersson E; Fredolini C; Forsström B; Reznichenko A; Akhter T; Ek WE; Bonfiglio F; Hansen MB; Sandberg K; Greco D; Repsilber D; Schwenk JM; D'Amato M; Halfvarson J
    Inflamm Bowel Dis; 2019 Jan; 25(2):306-316. PubMed ID: 30358838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between Long-Term Lipid Profiles and Disease Severity in a Large Cohort of Patients with Inflammatory Bowel Disease.
    Koutroumpakis E; Ramos-Rivers C; Regueiro M; Hashash JG; Barrie A; Swoger J; Baidoo L; Schwartz M; Dunn MA; Koutroubakis IE; Binion DG
    Dig Dis Sci; 2016 Mar; 61(3):865-71. PubMed ID: 26514677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel, objective, multivariate biomarkers composed of plasma amino acid profiles for the diagnosis and assessment of inflammatory bowel disease.
    Hisamatsu T; Okamoto S; Hashimoto M; Muramatsu T; Andou A; Uo M; Kitazume MT; Matsuoka K; Yajima T; Inoue N; Kanai T; Ogata H; Iwao Y; Yamakado M; Sakai R; Ono N; Ando T; Suzuki M; Hibi T
    PLoS One; 2012; 7(1):e31131. PubMed ID: 22303484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TWEAK is not elevated in patients with newly diagnosed inflammatory bowel disease.
    Grimstad T; Skoie IM; Doerner J; Isaksen K; Karlsen L; Aabakken L; Omdal R; Putterman C
    Scand J Gastroenterol; 2017 Apr; 52(4):420-424. PubMed ID: 28040992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bimodal plasma metabolomics strategy identifies novel inflammatory metabolites in inflammatory bowel diseases.
    Yau YY; Leong RW; Shin S; Bustamante S; Pickford R; Hejazi L; Campbell B; Wasinger VC
    Discov Med; 2014 Sep; 18(98):113-24. PubMed ID: 25227752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease.
    Karmiris K; Koutroubakis IE; Xidakis C; Polychronaki M; Voudouri T; Kouroumalis EA
    Inflamm Bowel Dis; 2006 Feb; 12(2):100-5. PubMed ID: 16432373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.